Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.
复制标题
贝伐珠单抗的全身给药可延长铂类预处理卵巢癌体内模型的生存期。
DOI：
10.3892/ol.2012.553
复制
发表时间：
2012
期刊：
影响因子：
2.9
通讯作者：
M. Breidenbach
中科院分区：
文献类型：
--
作者：
D. Rein;A. Volkmer;J. Volkmer;I. Beyer;W. Janni;M. Fleisch;A. Welter;D. Bauerschlag;T. Schöndorf;M. Breidenbach
卵巢癌患者常出现恶性腹水和胸腔积液。除了使结果恶化之外，这种情况还经常损害已经患有卵巢癌的患者的生活质量。本研究探讨单次腹腔注射抗 VEGF 抗体贝伐珠单抗是否能够减少腹水相关的体表面积并延长生存期。该研究是在腹膜播散性铂类耐药卵巢癌原位小鼠模型中进行的。用贝伐单抗和/或紫杉醇或缓冲液（对照）治疗小鼠。体表面积的减少和存活率的增加被评估为治疗成功。与未治疗对照组相比，所有治疗组小鼠的存活率均显着提高。与仅使用一种药物的治疗相比，紫杉醇加贝伐珠单抗的组合显着改善了体表面积和总体生存率。使用单剂量贝伐珠单抗腹腔注射治疗恶性积液，联合或不联合细胞抑制剂联合治疗，可能是全身治疗的有力替代方案。
Ovarian cancer patients often suffer from malignant ascites and pleural effusion. Apart from worsening the outcome, this condition frequently impairs the quality of life in patients who are already distressed by ovarian cancer. This study investigated whether single intraperitoneal administration of the anti-VEGF antibody bevacizumab is capable of reducing the ascites-related body surface and prolonging survival. The study was performed in an orthotopic murine model of peritoneal disseminated platin-resistant ovarian cancer. Mice were treated with bevacizumab and/or paclitaxel or buffer (control). Reduction of body surface and increased survival rates were assessed as therapeutic success. Survival of mice in all treatment groups was significantly enhanced when compared to the non-treatment control group. The combination of paclitaxel plus bevacizumab significantly improved body surface as well as overall survival in comparison to a treatment with only one of the drugs. Treatment of malignant effusion with a single dose of bevacizumab as an intraperitoneal application, with or without cytostatic co-medication, may be a powerful alternative to systemic treatment.
影响因子：
45.3
作者：
Burger, Robert A.;Sill, Michael W.;Sorosky, Joel I.
通讯作者：
Sorosky, Joel I.